ArticleThoracic cancer2016
Notch1 controls cell chemoresistance in small cell lung carcinoma cells.
Article in Thoracic cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Mechanisms of resistance in small cell lung cancer.Chinese medical journal · 2026Review
- NFIB Regulates Chemoresistance in Small Cell Lung Cancer by Suppressing Notch Signaling Activity.Cancer reports (Hoboken, N.J.) · 2026Article
- Molecular basis and therapeutic implications of binary YAPOn/YAPOff cancer classes.The Biochemical journal · 2025Review
- Prognostic and predictive impact of NOTCH1 in early breast cancer.Breast cancer research and treatment · 2025Article
- Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer.Nature reviews. Clinical oncology · 2024Review
- Role of Notch1 Signaling Pathway in Small Cell Lung Carcinoma.Iranian journal of pathology · 2024Review
- The role of YAP1 in small cell lung cancer.Human cell · 2022Article
- Targeting Notch to Maximize Chemotherapeutic Benefits: Rationale, Advanced Strategies, and Future Perspectives.Cancers · 2021Review
- The Notch1 gene may control cell chemoresistance in esophageal squamous cell cancer.Translational cancer research · 2021Article
- Identifying specific Notch1 target proteins in lung carcinoma cells.Histology and histopathology · 2021Article
- Overexpression of close homolog of L1 enhances the chemosensitivity of lung cancer cells via inhibition of the Akt pathway.Oncology letters · 2020Article
- New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts.Translational lung cancer research · 2020Review
- Effect of Wenxia Changfu Formula Combined With Cisplatin Reversing Non-Small Cell Lung Cancer Cell Adhesion-Mediated Drug Resistance.Frontiers in pharmacology · 2020Article
- Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.Cellular oncology (Dordrecht, Netherlands) · 2019Review
- MYCN-mediated regulation of the HES1 promoter enhances the chemoresistance of small-cell lung cancer by modulating apoptosis.American journal of cancer research · 2019Article
- PRKD2 Promotes Progression and Chemoresistance of AML via Regulating Notch1 Pathway.OncoTargets and therapy · 2019Article
- Doxorubicin combined with Notch1-targeting siRNA for the treatment of gastric cancer.Oncology letters · 2018Article
- Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer.Nature communications · 2018Article
- [MiR-433 reverses chemoresistance to docetaxel by targeting Notch1 in breast cancer cells].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2018Article
- Downregulation of long non-coding RNA LET predicts poor prognosis and increases Notch signaling in non-small cell lung cancer.Oncotarget · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSmall cell lung carcinoma (SCLC) is characterized by a high rate of relapse and failure of chemotherapy because of the emergence of drug resistant cells. Notch signaling controls carcinogenesis in several human malignancies and could be involved in the resistance of cells to several chemotherapeutic agents. Herein, we analyzed the role of Notch1 signaling in the resistance of human SCLC cells to doxorubicin.
methodsSmall interfering ribonucleic acid technology was used to knock down (KD) Notch1 in H69AR and SBC-3 SCLC cells. We detected the effect of inhibiting Notch1 on the expression of drug resistant related molecules: multidrug resistance-associated protein (MRP-1) and anti-apoptotic factor B-cell lymphoma-2, as well as to cell adhesion molecule E-cadherin, which contributes to the adhesion of SCLC cells to the extracellular matrix and confers chemoresistance in a process known as cell adhesion-mediated drug resistance (CAM-DR). We also observed the effect of KD Notch1 on cell survival under high concentrations of doxorubicin treated media.
resultsH69AR and SBC-3 cells expressed Notch1 protein and grew as adherent aggregates, which confer resistance to high concentrations of doxorubicin. On inhibiting Notch1, we observed activation of the apoptotic pathway in cells, possibly resulting from the loss of CAM-DR and, thus, SBC-3 cells showed a loss of chemoresistant ability. However, in H69AR cells with KD Notch1, the expression of MRP-1 was increased and, thus, sustained the chemoresistant ability of cells.
conclusionThe Notch1 signaling pathway is involved in mediating the drug resistance phenotype of SCLC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.